C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE
- PMID: 37052450
- DOI: 10.1097/CCM.0000000000005796
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE
Comment in
-
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study.Crit Care Med. 2023 Nov 1;51(11):e243-e244. doi: 10.1097/CCM.0000000000005956. Epub 2023 Oct 12. Crit Care Med. 2023. PMID: 37902353 No abstract available.
Comment on
-
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).Crit Care Med. 2022 Dec 1;50(12):1788-1798. doi: 10.1097/CCM.0000000000005683. Epub 2022 Oct 10. Crit Care Med. 2022. PMID: 36218354 Free PMC article. Clinical Trial.
References
-
- Carvelli J, Demaria O, Vély F, et al.: Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 2020; 588:146–150
-
- Vlaar APJ, Witzenrath M, van Paassen P, et al.: Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2022; 10:1137–1146
-
- Carvelli J, Meziani F, Dellamonica J, et al.; for the FOR COVID Elimination (FORCE) Study Group: Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]) Crit Care Med 2022; 50:1788–1798
-
- Harvey WT, Carabelli AM, Jackson B, et al.: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19:409–424
-
- Rittirsch D, Flierl MA, Nadeau BA, et al.: Functional roles for C5a receptors in sepsis. Nat Med 2008; 14:551–557
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources